Beclomethasone Dipropionate

Summary

Beclomethasone Dipropionate (CHEMBL1200500) is an approved small-molecule anti-inflammatory drug (ATC R03BA01) targeting ADGRG3; indicated across 23 conditions including allergic rhinitis and obstructive lung disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: R03BA01 (+3 more)
• Targets: 1 (ADGRG3)
• Indications: 23 conditions
• Clinical trials: 89
• Chemistry: 521 Da · C28H37ClO7

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200500
Name	Beclomethasone Dipropionate
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	21700
ChEBI	CHEBI:3002
ATC	R03BA01, D07AC15, R01AD01, A07EA07
Molecular formula	C28H37ClO7
Molecular weight	521
InChIKey	KUVIULQEHSCUHY-XYWKZLDCSA-N

SMILES: CCC(=O)OCC(=O)[C@]1([C@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)Cl)O)C)C)OC(=O)CC

IUPAC name: [2-[(8S,9R,10S,11S,13S,14S,16S,17R)-9-chloro-11-hydroxy-10,13,16-trimethyl-3-oxo-17-propanoyloxy-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] propanoate

ChEBI definition: A steroid ester comprising beclomethasone having propionyl groups at the 17- and 21-positions.

Pharmacological roles (ChEBI): anti-inflammatory drug, anti-asthmatic drug, prodrug, anti-arrhythmia drug.

Also known as: Aerobec 100, Aerobec 50, Aerobec fte 250, Asmabec clickhaler, Asmabec spacehaler, Beclazone 100, Beclazone 100 e-breathe, Beclazone 200, Beclazone 250, Beclazone 250 e-breathe, Beclazone 50, Beclazone 50 e-breathe

Patent coverage: 7,679 distinct patent families (29,239 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
ADGRG3	ADGRG3	Full agonist	8.5	0.6%	Q86Y34

Broader ChEMBL bioactivity targets: 9 (assay-derived). Sample: Mitochondrial import inner membrane translocase subunit TIM23, Androgen receptor, Beta-lactamase, Glucocorticoid receptor, Thromboxane A2 receptor, Progesterone receptor, Muscarinic acetylcholine receptor M1, Cannabinoid receptor 1, Adenosine receptor A3.

Bioactivity

ChEMBL activities: 7 potent at pChembl ≥ 5 of 10 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
NR3C1	8.22	AC50	6	nM	CHEMBL_ACT_25175978
PGR	8.17	AC50	6.7	nM	CHEMBL_ACT_25204526
PGR	7.34	AC50	46	nM	CHEMBL_ACT_25192853
AR	6.65	AC50	224.6	nM	CHEMBL_ACT_25203593
CNR1	5.55	AC50	2832	nM	CHEMBL_ACT_25181716
P00811	5.25	Potency	5623	nM	CHEMBL_ACT_4726434
ADORA3	5.2	AC50	6267	nM	CHEMBL_ACT_25198904

Target pathways

Aggregated over 1 target gene(s): ADGRG3.

Top Reactome pathways

3 total, by targets touching each:

Pathway	Targets	Genes
Innate Immune System	1	ADGRG3
Immune System	1	ADGRG3
Neutrophil degranulation	1	ADGRG3

Dominant GO biological processes

GO term	Targets
cell surface receptor signaling pathway	1
G protein-coupled receptor signaling pathway	1
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	1
B cell differentiation	1
regulation of cell migration	1
obsolete negative regulation of CREB transcription factor activity	1
negative regulation of non-canonical NF-kappaB signal transduction	1
signal transduction	1

Indications & clinical

Indications

5 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
allergic rhinitis	4	MONDO:0011786	EFO:0005854
obstructive lung disease	4	MONDO:0002267	HP:0006536
seasonal allergic rhinitis	4	MONDO:0005324	EFO:0003956
perennial allergic rhinitis	4	MONDO:0024332	EFO:1001417
asthma	4	MONDO:0004979	MONDO:0004979

14 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
chronic obstructive pulmonary disease	3	MONDO:0005002	EFO:0000341
graft versus host disease	3	MONDO:0013730	EFO:0004599
croup	3	MONDO:0005722	EFO:0007227
sinusitis	3	MONDO:0005961	EFO:0007486
bronchiectasis	3	MONDO:0004822	HP:0002110
newborn respiratory distress syndrome	3	MONDO:0700081	EFO:1000644
bronchopulmonary dysplasia	3	MONDO:0019091	MONDO:0019091
nasal cavity polyp	2	MONDO:0006314	EFO:1000391
idiopathic pulmonary fibrosis	2	MONDO:0800504	EFO:0000768
folliculitis	2	MONDO:0006552	EFO:1000702
small cell lung carcinoma	2	MONDO:0008433	EFO:0000702
severe acute respiratory syndrome	2	MONDO:0005091	MONDO:0100096
eosinophilic esophagitis	1	MONDO:0005361	EFO:0004232
enteritis	1	MONDO:0043579	MONDO:0043579

4 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 89.

Phase distribution

Phase	Trials
PHASE3	32
PHASE4	24
PHASE2	14
Not specified	10
PHASE1	5
PHASE2/PHASE3	2
PHASE1/PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06571942	PHASE4	RECRUITING	Effect of the Inhaled Triple Therapies Over the Small Airway in Biomass Exposure
NCT00071552	PHASE4	TERMINATED	Efficacy of QVAR vs Flovent Diskus on Small Airways in Poorly Controlled Asthmatic Adolescents/Adult Patients
NCT00250341	PHASE4	COMPLETED	Non-invasive Measures of Distal Lung Disease in Asthmatics
NCT00532584	PHASE4	WITHDRAWN	Effect of Steroids on Gene Expression in the Healthy Smokers Lungs
NCT00826748	PHASE4	TERMINATED	Effect of Inhaled Steroids on Gene Expression in the Lungs - 2
NCT00962299	PHASE4	TERMINATED	Effectiveness of Inhaled Corticosteroids in Preschool Children With Acute Dyspnea and Wheeze
NCT01265342	PHASE4	COMPLETED	Efficacy of Nebulised Beclometasone in Viral Wheezing Prophylaxis
NCT01333800	PHASE4	COMPLETED	Cost-effectiveness Study of Beclomethasone Versus Ciclesonide as Controller Medications in Pediatric Asthma
NCT01466712	PHASE4	UNKNOWN	Evaluate the Effects of Formoterol and Beclomethasone Dipropionate Combination Therapy on Small Airways Function
NCT01520688	PHASE4	COMPLETED	Effect of Flovent Discus vs QVAR vs Pulmicort Flexhaler on Short Term Growth
NCT01550471	PHASE4	COMPLETED	Sunovion Growth Study Pediatric Subjects With Mild Asthma & Allergic Rhinitis
NCT01656005	PHASE4	COMPLETED	Beta Blocker Therapy in Moderate to Severe COPD
NCT01741285	PHASE4	COMPLETED	Effects of QVAR in Smokers With Asthma
NCT01852513	PHASE4	COMPLETED	Allergic Rhinitis Changes the Sinus Microbiome
NCT02294279	PHASE4	COMPLETED	The Evaluation of FeNO for Predicting Response to ICS in Subjects With Non-specific Respiratory Symptoms
NCT02319564	PHASE4	WITHDRAWN	Combined Glucocorticoid Adrenergic Therapy For Wheezy Preschool Children
NCT02345993	PHASE4	UNKNOWN	Extra-fine Formoterol/Beclomethasone in Asthmatic Crisis
NCT02526758	PHASE4	UNKNOWN	Small Airways Evaluation and Treatment
NCT02577497	PHASE4	COMPLETED	Effect of Extra- Fine Versus Coarse-Particle Inhaled Corticosteroids (ICS) on Ventilation Heterogeneity in Children With Poorly Controlled Asthma
NCT02687100	PHASE4	WITHDRAWN	The Effects of Beclomethasone Upper the Endotracheal Cuff on the Occurrence of Sore Throat at Extubation
NCT03369847	PHASE4	COMPLETED	Inhaled Steroids for Pediatric Asthma at Pediatric Emergency Medicine Discharge
NCT03842904	PHASE4	COMPLETED	A Study Comparing the Effects of Trimbow to Fostair in COPD
NCT04671355	PHASE4	WITHDRAWN	TRIMBOW® and RELVAR® on Lung Stiffness Reduction Assessed Through Forced Oscillation Technique in Patients With COPD
NCT05352191	PHASE4	UNKNOWN	Beclomethasone in Healthy Athletes
NCT00000576	PHASE3	COMPLETED	Inhaled Beclomethasone to Prevent Chronic Lung Disease
NCT00000578	PHASE3	COMPLETED	NHLBI/NICHD Collaborative Studies of Asthma in Pregnancy
NCT00043147	PHASE3	COMPLETED	Beclomethasone Plus Prednisone in Treating Patients With Graft-Versus-Host Disease
NCT00094016	PHASE3	COMPLETED	Evaluation of Two Doses of QVAR by Breath Operated and Metered Dose Inhalers in Asthmatic Children
NCT00119496	PHASE2/PHASE3	COMPLETED	Rosiglitazone Versus Theophylline in Asthmatic Smokers
NCT00346775	PHASE3	COMPLETED	Validation Of Preference Module Of Experience With Allergic Rhinitis Nasal Sprays Questionnaire (EARNS-Q)
NCT00382889	PHASE3	COMPLETED	As Needed Beclomethasone/Salbutamol Combination in Single Inhaler for Mild Persistent Asthma
NCT00394329	PHASE3	COMPLETED	(CARE Network Trial - Treating Children to Prevent Exacerbations of Asthma (TREXA)
NCT00476099	PHASE3	COMPLETED	Efficacy and Safety Study of Beclometasone/Formoterol Single Inhaler in Patients With COPD
NCT00476268	PHASE3	COMPLETED	Efficacy and Tolerability of Beclometasone/Formoterol Single Inhaler in Patients With Moderate to Severe Persistent Asthma
NCT00497523	PHASE3	COMPLETED	Efficacy and Safety of Nebulised Beclomethasone Dipropionate Plus as Needed Salbutamol vs as Needed Salbutamol or as Needed Salbutamol/Beclomethasone Fixed Combination in Young Children With Asthma Symptoms
NCT00565266	PHASE3	COMPLETED	Asthma Clinical Research Network (ACRN) Trial - Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC)
NCT00861926	PHASE3	COMPLETED	Study on Foster Efficacy Maintenance and Reliever vs Foster Maintenance + Salbutamol Reliever in Asthmatics (MART2)
NCT00911547	PHASE3	COMPLETED	The Clinical Effect of MK0476 With Concomitant Administration of and Removal of Inhaled Beclomethasone in Asthmatic Patients (0476-029)
NCT00926575	PHASE3	TERMINATED	Study of orBec® With Prednisone Therapy in the Treatment of Patients With Graft Versus Host Disease (GVHD)
NCT00988247	PHASE3	COMPLETED	Long Term Safety and Efficacy Trial of Beclomethasone Dipropionate - Hydrofluoroalkane (BDP-HFA) 320 mcg in Allergic Rhinitis
NCT01024608	PHASE3	COMPLETED	Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)
NCT01113489	PHASE3	COMPLETED	Assessment of Oxidative Stress Markers in the Upper and Lower Airways of Atopic Children Treated With Nebulized Beclomethasone
NCT01133626	PHASE3	COMPLETED	Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subjects With Perennial Allergic Rhinitis (PAR)
NCT01244256	PHASE2/PHASE3	SUSPENDED	Efficacy and Comparative of the Association Beclomethasone Clotrimzaol + Gentamicin in Patients With Acne Contaminated
NCT01450774	PHASE3	COMPLETED	Comparison of Combination of Beclomethasone Dipropionate and Formoterol Fumarate Versus Single Components Assessed by Knemometry and Urinary Cortisol Measurements in Asthmatic Children
NCT01475032	PHASE3	COMPLETED	Efficacy Study of the Product CHF 1535 Versus Beclomethasone (BDP) and Free Combo in Asthmatic Children
NCT01691677	PHASE3	COMPLETED	beCLomethasone Efficacy in Acute Rhinosinusitis - CLEAR Study
NCT01917331	PHASE3	COMPLETED	Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate Versus Foster® in COPD
NCT02031640	PHASE3	COMPLETED	A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma
NCT02113072	PHASE3	COMPLETED	Recurrent Wheezing in Infants: Risk Factors and Prevention With Probiotics.
NCT02139644	PHASE3	COMPLETED	Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma
NCT02513160	PHASE3	COMPLETED	Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma
NCT03268226	PHASE3	COMPLETED	Functional Respiratory Imaging Study (FRI)
NCT03834012	PHASE3	WITHDRAWN	Beclomethasone Dipropionate HFA in Adult and Adolescent Subjects With Persistent Asthma
NCT04320342	PHASE3	COMPLETED	A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD
NCT04876677	PHASE3	COMPLETED	Functional Respiratory Imaging Study (DARWiIN)
NCT04886999	PHASE3	COMPLETED	Study in Adult Patients With Moderate to Severe Asthma
NCT05292586	PHASE3	COMPLETED	A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid
NCT07282886	PHASE2	RECRUITING	VENTURI (VENTilation Using Respiratory Imaging)
NCT00000752	PHASE2	WITHDRAWN	Preventing Frequent Sinus Infections in HIV-Infected Patients
NCT00010283	PHASE1/PHASE2	COMPLETED	Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon
NCT00115089	PHASE2	COMPLETED	7 Day Study of Mast Cell Inhibitor, R926112, in Patients With Symptomatic Seasonal Allergic Rhinitis
NCT00489203	PHASE2	COMPLETED	Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
NCT01544634	PHASE2	COMPLETED	Beta Blocker Therapy in Mild to Moderate Asthmatics
NCT01584492	PHASE2	COMPLETED	Bronchodilator Effect of CHF1535 pMDI Versus Free Combination of Beclometasone Plus Formoterol pMDI in Asthmatic Children
NCT01650441	PHASE2	COMPLETED	Study to Assess the Effect of the NEXThaler® Device (DPI - Dry Powder Inhaler) on the Central and Peripheral Airway Dimensions in Asthmatic Patients
NCT02048644	PHASE2	COMPLETED	Effect of Fostair® on Biomarkers of Platelet Adhesion in Idiopathic Pulmonary Fibrosis
NCT02148120	PHASE2	COMPLETED	A Study to Evaluate the Acute Bronchodilator Effect of CHF1535 NEXThaler
NCT02296411	PHASE2	COMPLETED	Efficacy of LAMA Added to ICS in Treatment of Asthma (ELITRA)
NCT02351180	PHASE1/PHASE2	COMPLETED	Inhaled Beclomethasone After Community-Acquired Respiratory Viral Infection in Lung Transplant Recipients
NCT02517099	PHASE2	COMPLETED	Preschool Wheeze: Inflammation/Infection Guided Management
NCT03886441	PHASE2	UNKNOWN	Prevention of Locally Advanced NSCLC Radiotherapy Pneumonia by Inhaling Beclomethasone Propionate
NCT04294641	PHASE2	COMPLETED	Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease
NCT05970731	PHASE2	COMPLETED	Directed Topical Drug Delivery for Treatment for PASC Hyposmia
NCT01016223	PHASE1	COMPLETED	A Randomized Double Blind Placebo Controlled Study of the Effect of Swallowed Beclomethasone Dipropionate on Inflammatory Markers in Adult Patients With Eosinophilic Esophagitis
NCT02040597	PHASE1	COMPLETED	A Study to Investigate the Pharmacokinetics, Safety and Tolerability of CHF 5993 pMDI in Subjects With Renal Impairment.
NCT02119234	PHASE1	COMPLETED	Pharmacokinetics of CHF 5993 pMDI With and Without Spacer in COPD Patients
NCT02975843	PHASE1	COMPLETED	Lung Deposition of Beclometasone Dipropionate/Formoterol Fumarate/Glycopyrronium Bromide Administered Via pMDI in Healthy, Asthmatic and COPD Patients
NCT04873063	PHASE1	COMPLETED	Evaluation of Systemic Bioavailability and Effects on 24-Hour Plasma Cortisol Profile of 6 mg Delivered Once Daily Versus 3 mg Delivered Twice Daily in Healthy Adult Male Volunteers
NCT07267273	Not specified	RECRUITING	Betamethasone Phonophoresis For Vitiligo
NCT00055666	Not specified	COMPLETED	Compassionate Use of Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Gastrointestinal Tract
NCT01141439	Not specified	COMPLETED	Real-world Effectiveness and Cost-effectiveness of Leading Inhaled Corticosteroids in Asthma Management
NCT01142947	Not specified	COMPLETED	Study of Asthma Phenotypes and Pharmacogenomic Interactions by Race-Ethnicity (SAPPHIRE)
NCT01224951	Not specified	UNKNOWN	Development and Validation of a Sputum Biomarker mRNA Panel for the Diagnostic Work-up of Asthma 2
NCT02133053	Not specified	COMPLETED	Application of Ectoin Allergy Nasal Spray in Comparison to Beclomethasone Nasal Spray
NCT03627858	Not specified	COMPLETED	Fixed Dose Triple Therapy in Severe Chronic Obstructive Pulmonary Disease in a Real World Setting
NCT04421742	Not specified	COMPLETED	The Effect of Beclomethasone/Formoterol in Extra-fine Formulation on Quality of Life and SAD in COPD Patients.
NCT05888350	Not specified	COMPLETED	Biomarkers for Predicting the Response to Inhaled Corticosteroid in Patients With Chronic Cough.
NCT05948891	Not specified	UNKNOWN	Impact of Fixed TRIple Therapy With Beclometasone/Formoterol/Glycopyrronium DPI (Trimbow® in NEXThaler Device) in Chronic Obstructive PulmoNary Disease in rEal-world Settings: Health-related Quality of Life Patient’ eXpectations and characterisTics: the TriNEXT Study

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 0 clinical and 1 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).